Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Economic information and modeling reportBudget impact model

Epidemiology and eligible population inputs

5 evidence topics · 4 sources

ICER potential budget impact analysis: eligible population and uptake

“To estimate the size of Population 1 (those taking three or more antihypertensive medications but still not achieving blood pressure goals), we used inputs for the overall prevalence of hypertension among US adults (48.1%)” (opens the source at this quote in a new tab)

“the percentage of those with hypertension who are taking medication (51.2%)” (opens the source at this quote in a new tab)

“and the percentage of those taking medication who are being treated with three or more antihypertensive medications but still have uncontrolled hypertension (15%)” (opens the source at this quote in a new tab)

“Applying these sources to the overall adult population in the US averaged over the next five years (271,862,765) results in estimates of 10,042,828 eligible patients in the US. For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 2,008,565 patients per year.” (opens the source at this quote in a new tab)

“who are being treated with two antihypertensive medications and still have uncontrolled hypertension (17.9%)” (opens the source at this quote in a new tab)

“We then assumed that 21% of these have attempted a third antihypertensive medication and discontinued. This is a placeholder estimate based on available claims data reporting discontinuation rate of antihypertensive medications” (opens the source at this quote in a new tab)

“As a result, we estimated that 2,516,732 patients have uncontrolled hypertension and have attempted and discontinued a third antihypertensive medication (Population 2). For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 503,346 patients per year. Between Population 1 and Population 2 we estimated a total of 12,559,560 eligible patients.” (opens the source at this quote in a new tab)